| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
3β,5α,6β-Trihydroxycholestane does not have a defined primary drug target as it is primarily a research compound and sterol intermediate rather than a therapeutic agent. As a naturally occurring steroid, it may interact with steroid hormone receptors or enzymes involved in steroid biosynthesis and metabolism. The compound's three hydroxyl groups at the 3β, 5α, and 6β positions confer unique hydrogen-bonding capabilities that can influence membrane interactions. Its role in studying sterol phase behavior suggests it may interact with membrane components, affecting lipid bilayer organization and fluidity.
|
|---|---|
| ln Vitro |
3β,5α,6β-Trihydroxycholestane is an organic substance or biomaterial that can be utilized as a biochemical reagent in life science research.
As a sterol research compound, 3β,5α,6β-Trihydroxycholestane is not typically evaluated for direct in vitro biological activity against specific molecular targets in drug discovery contexts. However, its effects on membrane properties have been studied in vitro using model membrane systems. The compound influences sterol phase behavior and membrane rigidity, affecting bilayer ordering and permeability. These membrane-modulating effects can indirectly influence cellular processes such as signal transduction and membrane protein function. The compound's biological relevance stems primarily from its role as a sterol intermediate and membrane component. |
| ln Vivo |
In vivo activity data for 3β,5α,6β-Trihydroxycholestane itself is limited, as the compound is primarily used as a research tool for studying sterol biochemistry and membrane biophysics rather than as a therapeutic agent. The compound's potential therapeutic and environmental applications have gained attention in recent years. As a sterol intermediate, it may be involved in steroid hormone biosynthesis pathways in vivo. Its effects on membrane properties suggest potential relevance to conditions involving membrane dysfunction, though comprehensive in vivo studies have not been extensively reported.
|
| Enzyme Assay |
Cell-free biochemical assays for 3β,5α,6β-Trihydroxycholestane typically focus on its effects on model membrane systems rather than enzyme inhibition. A standard protocol involves preparing liposomes or other model membranes with varying concentrations of the sterol, and assessing membrane properties using techniques such as fluorescence anisotropy, differential scanning calorimetry, or neutron scattering. The compound's effects on membrane rigidity and phase behavior are measured by tracking changes in lipid packing and order parameters. Alternatively, the compound can be used as a standard or reference material in sterol analysis by HPLC or GC-MS. Assays are performed in triplicate with appropriate controls.
|
| Cell Assay |
Cell-based assays for 3β,5α,6β-Trihydroxycholestane typically evaluate its effects on membrane properties and cellular functions in cultured cells. A standard protocol involves culturing cells (e.g., fibroblasts or epithelial cells) in appropriate media, treating with the compound at concentrations ranging from 1-100 μM for 24-72 hours, and assessing membrane fluidity using fluorescent membrane probes such as Laurdan or DPH. Cellular cholesterol content and sterol composition can be analyzed by lipid extraction followed by HPLC or GC-MS. Cell viability is assessed by MTT or other assays to confirm that observed effects are not due to cytotoxicity.
|
| Animal Protocol |
In vivo studies with 3β,5α,6β-Trihydroxycholestane are limited, as the compound is primarily a research tool for in vitro applications. If conducted, a typical protocol might involve administration of the compound to rodents by oral gavage or intraperitoneal injection, followed by analysis of sterol composition in tissues and assessment of membrane properties. Tissues would be collected at various time points and analyzed for sterol content by GC-MS. However, comprehensive in vivo efficacy studies have not been extensively reported for this compound. The compound's primary applications remain in membrane biophysics and sterol biochemistry research.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 3β,5α,6β-Trihydroxycholestane is limited, as the compound is primarily used in research settings. The molecular weight is 420.67 g/mol. As a sterol, the compound is highly lipophilic and would be expected to associate with lipid membranes and lipoproteins. For in vivo applications, the compound would likely require formulation with appropriate vehicles to enhance bioavailability. The compound is typically dissolved in organic solvents such as ethanol or DMSO for in vitro studies. Metabolism would involve oxidation and conjugation reactions similar to other sterols.
|
| Toxicity/Toxicokinetics |
Toxicological data specific to 3β,5α,6β-Trihydroxycholestane is limited, as the compound is a research chemical used primarily in laboratory settings. The compound is a naturally occurring sterol and is not intended for human or veterinary use. At concentrations used in research (typically low micromolar range), the compound does not show significant cytotoxicity in most cell types. Standard laboratory safety precautions should be observed when handling this compound. As a sterol, its toxicological profile would be expected to differ from that of synthetic steroids.
|
| Additional Infomation |
5α-Cholesterane-3β,5,6β-triol is a 3β-hydroxysteroid, 6β-hydroxysteroid, and 5α-hydroxysteroid compound. It is derived from the hydride of 5α-cholestane. 3β,5α,6β-trihydroxycholestane has been reported in Eunicea laciniata, Echinogorgia aurantiaca, and Plexaurella grisea, and relevant data are available.
3β,5α,6β-Trihydroxycholestane is a research compound and not an approved drug. No clinical trials or regulatory approvals exist for this compound. It is commercially available from various suppliers for research purposes only. The compound's primary value lies in its utility as a research tool for studying sterol biochemistry, membrane biophysics, and steroid biosynthesis. As a naturally occurring sterol intermediate, it provides a benchmark for understanding the structural evolution of sterols in biological membranes and their influence on bilayer ordering and permeability. The compound is also used as a pharmaceutical standard, impurity reference, and metabolite standard. |
| Molecular Formula |
C27H48O3
|
|---|---|
| Molecular Weight |
420.67
|
| Exact Mass |
420.36
|
| CAS # |
1253-84-5
|
| Related CAS # |
3β,5α,6β-Trihydroxycholestane-d7;127684-07-5
|
| PubChem CID |
91498
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
515.7±40.0 °C at 760 mmHg
|
| Flash Point |
212.5±21.9 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.538
|
| LogP |
7.73
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
30
|
| Complexity |
619
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@H]([C@@]4([C@@]3(CC[C@@H](C4)O)C)O)O)C
|
| InChi Key |
YMMFNKXZULYSOQ-RUXQDQFYSA-N
|
| InChi Code |
InChI=1S/C27H48O3/c1-17(2)7-6-8-18(3)21-9-10-22-20-15-24(29)27(30)16-19(28)11-14-26(27,5)23(20)12-13-25(21,22)4/h17-24,28-30H,6-16H2,1-5H3/t18-,19+,20+,21-,22+,23+,24-,25-,26-,27+/m1/s1
|
| Chemical Name |
(3S,5R,6R,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,5,6-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3772 mL | 11.8858 mL | 23.7716 mL | |
| 5 mM | 0.4754 mL | 2.3772 mL | 4.7543 mL | |
| 10 mM | 0.2377 mL | 1.1886 mL | 2.3772 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
